Last checked at 29 Sep 2021 11:08
Hutchmed China sells joint venture stake for USD169 million
Hutchmed China sells joint venture stake for USD169 million
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hutchmed Share News (HCM)
HCM Share
Price
HCM Share
News
HCM Share
Chat
HCM Share
Trades23
HCM
Live RNS
HCM Share
Charts
HCM Level 2
Console
HCM Live
Share Price
HCM Broker
Ratings
HCM Directors
Deals
HCM Financial
Diary
HCM
Fundamentals
HCM Short
Positions
HCM
Media
Hutchmed Information
Share Price Information for Hutchmed (HCM)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
270.00
Bid:
265.00
Ask:
269.00
Change:
-1.00 (-0.37%)
Spread:
4.00 (1.509%)
Open:
266.00
High:
270.00
Low:
261.00
Prev. Close:
271.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.21 Sep 2021 10:51
Hutchmed starts drug combination trial for neuroendocrine tumours
Hutchmed starts drug combination trial for neuroendocrine tumours
Read more20 Sep 2021 09:09
Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors
Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors
Read more13 Sep 2021 10:22
Hutchmed China's amdizalisib secures breakthrough therapy designation
Hutchmed China's amdizalisib secures breakthrough therapy designation
Read more8 Sep 2021 13:49
Hutchmed, Astra launch drug combination trial to treat lung cancer
Hutchmed, Astra launch drug combination trial to treat lung cancer
Read more6 Sep 2021 09:37
Hutchmed China to trade in Shanghai and Shenzhen through link scheme
Hutchmed China to trade in Shanghai and Shenzhen through link scheme
Read more26 Aug 2021 10:38
Hutchmed launches trial into drug combination to treat breast cancer
Hutchmed launches trial into drug combination to treat breast cancer
Read more9 Aug 2021 12:35
Hutchmed strikes collaboration deal with Epizyme
(Sharecast News) - Commercial-stage biotechnology company Hutchmed China announced a collaboration to research, develop, manufacture and commercialise 'Tazverik' in Greater China on Monday, including mainland China, Hong Kong, Macau and Taiwan.
Read more9 Aug 2021 10:06
Hutchmed to partner with Epizyme on tumour-targetting treatment
Hutchmed to partner with Epizyme on tumour-targetting treatment
Read more28 Jul 2021 14:51
Hutchmed research costs deepen loss; expects US launches in 2022, 2023
Hutchmed research costs deepen loss; expects US launches in 2022, 2023
Read more28 Jul 2021 11:33
IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial
IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial
Read more28 Jul 2021 10:58
AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%
AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%
Read more21 Jul 2021 16:12
UK earnings, trading statements calendar - next 7 days
UK earnings, trading statements calendar - next 7 days
Read more16 Jul 2021 11:19
AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks
AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks
Read more16 Jul 2021 10:55
IN BRIEF: Hutchmed tumor drug qualifies for formal review by EU agency
IN BRIEF: Hutchmed tumor drug qualifies for formal review by EU agency
Read more